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Abstract
Six children are presented with an isolated complex III deficiency in musclc tissue. More specifically, oxidation rates and ATP + CrP 
production rates from both pyruvate and succinate as substrates and/or the activity of decylubiquinolxytochrome c oxidoreductase were 
all markedly reduced. Complex III deficiency was also present in liver of two patients tested, but could not be demonstrated in cultured 
fibroblasts of four patients tested. Mitochondrial DNA, extracted from muscle, was analyzed; no deletions or common point mutations 
were found, Four patients presented with a multi-organ disorder. Among these patients three presented at neonatal age with neurological 
signs and lactate elevation in blood and CSF, of whom two had severe neonatal Fanconi syndrome, One child, aged seven years, had 
encephalomyopathy, ophthalmoplegia, retinopathy and Wolfi-Parkinson-White syndrome, The remaining two patients exhibited myopathy 
only, within the first year of life. Thus, like in other respiratory chain disorders, patients with complex III deficiency may present at any 
age and show variable symptoms and outcome, ranging from neonatal death to failure to thrive only. Apparently there are no clinical 
findings which are specific for complex III deficiency. © 1997 Elsevier Science B.V.
Keywords: Mitochondrial encephalomyopathy; Complex III; Decylubiquinolxytochrome c oxidoreductase; Fanconi syndrome; Respira­
tory chain
1. Introduction
Disorders of oxidative phosphorylation are degenerative 
diseases with a wide spectrum of clinical manifestation. In 
most cases the term mitochondrial encephalomyopathy is 
appropriate, because it refers to the tissues that appear to 
be affected most frequently by one of the biochemical 
defects involved. However, every organ can be affected 
and tissue-specific expression of oxidative phosphorylation 
defects appear to be frequent (Munnich et al„ 1992; 
Robinson, 1993; Shoffner and Wallace, 1995). In the group 
of mitochondrial disorders some circumscript clinical
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presentations are recognized which are associated with 
mitochondrial DNA (mtDNA) point mutations or deletions 
(Shoffner and Wallace, 1995). In most pediatric patients 
suffering from mitochondrial encephalopathy the clinical 
picture does not fit in one of these distinct presentations 
and no mutation in the mtDNA is found (Tulinius et al., 
1991a,b). In all these patients, demonstrating abnormal 
biochemistry of oxidative phosphorylation in skeletal 
muscle is the most important measure in the diagnostic 
process (Trijbels et al., 1988).
Oxidative phosphorylation is mediated by five mito­
chondrial enzyme complexes, which are named complex I 
(NADH: ubiquinone oxidoreductase), complex II (succi­
nate: ubiquinone oxidoreductase), complex III (ubiquinol: 
cytochrome c oxidoreductase), complex IV (cytochrome c
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oxidase) and complex V (ATP synthase). Complexes I and
II accept electrons from various sources and transfer them 
to ubiquinone. The electrons are further transmitted 
through complex III, cytochrome c and complex IV and 
finally react with oxygen, the terminal electron acceptor. 
Complex V mediates ATP synthesis. Each enzyme com­
plex consists of a number of subunits which are encoded 
by nuclear DNA and partly by mtDNA, except for 
complex II, which is entirely encoded by nuclear DNA. 
Complex III is composed of eleven subunits among which 
only one, cytochrome b, is encoded by mitochondrial 
DNA. The ten remaining subunits, among them the non­
heme iron-sulfur (von Rieske) protein, two large core 
proteins and cytochrome c p are encoded by nuclear DNA.
Deficiencies of complex I and complex IV, either 
isolated or combined, occur frequently, whereas complex
III deficiencies are rare. Due to a variety of descriptions of 
large groups of patients with complex I and/or complex IV 
deficiencies (DiMauro et al., 1990; Korenke et al„ 1990; 
Robinson, 1993), the wide spectrum of biochemical data 
and clinical presentations in these oxidative phosphoryla­
tion disorders is well known. However, only little is known 
about complex III deficiency in childhood. Here we report 
upon different clinical presentations of the disease in 
pediatric patients with isolated complex III deficiency of 
the respiratory chain.
2. Materials and methods
2.1. Patients
In this study only subjects are included in whom 
biochemical investigation of skeletal muscle revealed a 
defect in the respiratory chain localized at the level of 
complex III. Since such a block ought to impair utilisation 
of both N A D -linked  and FAD-linked substrates, the 
following criteria had to be fulfilled: (1) Decreased 
oxidation rates measured in fresh skeletal muscle superna­
tant with pyruvate, mal ate and succinate as substrates as 
well as decreased ATP and creatine phosphate (CrP) 
production rates using pyruvate and succinate as sub­
strates. (2) Reduced activities of decylubiquinol;cytoch­
rome c oxidoreductase (reflecting complex III capacity), 
and succinate:cytochrome c oxidoreductase (reflecting 
complexes 11+III capacity, CoQ content included); this in 
combination with normal activities of NADH:ubiquinone 
oxidoreductase (reflecting complex I capacity), cytochrome 
c oxidase (reflecting complex IV capacity) and pyruvate 
dehydrogenase. The biochemical investigations in muscle 
and liver tissue and in skin fibroblasts were performed at 
the University Hospital of Nijmegen. Details of the 
patients’ clinical features, clinical-biochemical data and 
muscle morphology were obtained retrospectively from, the 
case notes. Data from patient 1 and 2 have been reported 
previously (Sperl et al., 1988; Wendel et al., 1995).
2.2. Methods
Material for biochemical and morphological investiga­
tions was obtained by a surgical biopsy of the quadriceps 
muscle and by needle biopsy of the liver (patient 1 and 2). 
Skin fibroblasts were grown in M l99 medium, according 
to standard procedures.
Substrate oxidation rates and ATP-fCrP production rates 
from different substrates were measured in 600 g super­
natant s derived from homogenätes of fresh skeletal muscle 
tissue (stored at 0 °C for less than 1 h). Mitochondrial 
enzyme activities were measured in 600 g sup er nat ants of 
fresh or frozen (stored at - 7 0  °C) muscle tissue. The test 
procedures and selection criteria for control muscle speci­
mens have been described previously (Fischer et al., 
1986). Complex III activity was measured using de­
cylubiquinol as substrate, according to the method of 
Zheng (Zheng et al., 1990). However, Tween 20 [0.04% 
(v/v)] was added to the assay mixture in order to reduce 
the non-enzymatic reaction. Enzyme activities were also 
measured in mitochondria enriched fractions from cultured 
fibroblasts which were prepared by homogénisation and 
subsequent differential centrifugation (600 g and 14 000 g) 
of approximately 2 0 X 106 cells.
Substrate oxidation rates, ATP+ CrP production rates 
and enzyme activities were normalized to citrate synthase 
to correct for differences in mitochondrial content and 
recovery. In studies with frozen muscle specimens and 
cultured fibroblasts cytochrome c oxidase was used as the 
reference enzyme. In all samples studied activities of both 
reference enzymes were within the control ranges. Because 
recovery of mitochondria from liver tissue is invariably 
high, results in studies with frozen liver specimens were 
not normalized to a reference enzyme. Mitochondrial DNA 
was screened for large deletions and common point 
mutations as reported earlier (De Vries et al., 1993).
3. Results
Biochemical investigations in skeletal muscle tissue 
revealed an isolated complex III deficiency in six children. 
The data are specified in Table 1. From four patients fresh 
muscle tissue was available, whereas in two patients only 
frozen muscle specimens could be investigated. In super- 
natants derived from fresh muscle tissue the oxidation and 
ATP+ CrP production rates from both pyruvate and succi­
nate as substrates were found to be severely diminished in 
each patient (<40%  of the lowest control values), as were 
the activities of complex III (<40%  of the lowest control 
value). In frozen muscle specimens the complex III activity 
was diminished to 40% (Patient 1) and 80% (Patient 6 ) of 
the lowest control value. In all patients the activity of 
succinatexytochrome c oxidoreductase, reflecting complex 
11+III capacity, was also diminished, except for Patient 6, 
in whom activity was low normal. Activities of complex I,
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Table 1
Substrate oxidation, ATP+CrP production rates and enzyme activities of the respiratory chain complexes (600 g supernatant derived from muscle
snprtmp.n^peci ens)
F re s h  muscle Oxidation1 o f A TP+CrP production1 from Enzyme activities
pyruvate ( +  nialate) succinate ( +  acetylcamitine) pyruvate succinate N A DH :Q f 
(Complex I)
SCC3
(Complex 11+111)
QCC2
(Complex 111)
C O X '
(Complex IV)
Control range 
Pattern 2 
Patient 3 
Patient 4 
Patient 5
3 .6-7 .5  (;i =  13) 
1.3 
0.6 
2.2 
0.8
2 .5 -6 .4  (/?= 13)
0.8
0.1
0.2
0.7
42-82  (/j =  16) 
12.0 
4.3 
16.5 
5.2
7 .2 -18 .4  (n = 13)
3.2
n.d.
n.d.
2.6
0 .04-0 .13 («= 37) 
0.12 
0.05 
0.10 
0.12
0.28-2 .66 («=38) 
0.24 
0.01 
0.26 
0.14
2.9-9.0 (h =20)
0.7
n.d.
0.4
1.3
0.8-7.1 (/I= 6 8 )  
1.2 
0.7 
1.8
1.0
F ro z e n  muscle NADH:QÎ SCC* Qcc3 cox'
Control range 
Patient 1 
Patient 6
Frozen muscle is not assayed for oxidation 0.07-0 .29 (« =  11)
0.07
0.31
0.09-0.34 («=11)
0.03
0.12
l.5 -2 .5  («=15) 
0.6 
1.2
40-225  (»= 12)
73
42
J
Activities in nmoles/min-mU cilrate synthase.
3 Activities in mU/mU citrate synthase.
3 Activities in mU/mU cytochrome c oxidase, 
n.d.; not detectable.
NADH:Q,: NADH:ubiquinone oxidoreductase; SCC: Succinatexytochrome c oxidoreductase; QCC: Decylubiquinolxytochrome c oxidoreductase; COX: 
Cytochrome c oxidase.
complex IV and pyruvate dehydrogenase complex (data not 
shown) were all within the control range.
Liver tissue was investigated in two patients (Patients 1 
and 2, Table 2). In both specimens decylubiquinolxytoch- 
rome c oxidoreductase and succinatexytochrome c oxido­
reductase activities were clearly diminished, whereas the 
other respiratory chain enzyme activities were within the 
control range. This demonstrates that in both patients 
complex III deficiency was also expressed in liver, Cul­
tured fibroblasts from four patients (Patients 1-4) were 
studied. In none of the cell lines could complex III 
deficiency be demonstrated (data not shown).
Mitochondrial DNA, extracted from the muscle speci­
mens, was screened for large deletions and the point 
mutations on nucleotide positions 3243 (MELAS) and 
8993 (NARP/Leigh). In no patient was a deletion or point 
mutation detected.
Clinical and laboratory data of the complex III deficient 
patients are listed in Table 3. Among the six children, three 
presented in the neonatal period with hyperlactic acidemia, 
two with myopathic features in infancy and one with 
encephalomyopathy only at the age of 7 years. Family 
history was negative with respect to neuromuscular dis­
eases in all patients. Two siblings of Patient 1 had died of 
an unknown cause in the neonatal period (in Turkey). 
Patients 2 and 5 had consanguineous parents. In all patients
muscle biopsy showed nonspecific morphological changes 
and frequently ultrastructural abnormalities of mitochon­
dria, but no ragged-red fibres.
3A. Patients with multiorgan involvement
Four patients (Patients 1-4) had a complex multiorgan 
disorder. Three of them (Patients 1-3) presented in 
infancy with a combination of neurological disease, hy­
perlactic acidemia and an increased lactate/pyruvate ratio 
in blood. They showed pre- and postnatal growth retarda­
tion and the course of disease was progressive in three of 
them. Among them two developed a severe neonatal renal 
tubulopathy (De Toni-Fanconi-Debré syndrome). Patient 1 
had severe lactic acidosis and renal tubulopathy immedi­
ately after birth. Although the acidosis could be controlled 
the child showed failure to thrive and severe psychomotor 
retardation. Despite therapy with biotin, thiamine and 
carnitine she deteriorated with respiratory distress. At the 
age of 8 months she died of sudden respiratory arrest. 
Patient 2 was referred at the age of 2 months because of 
failure to thrive. On admission he showed severe hypo­
tonia, irritability, rickets and signs of proximal renal 
tubulopathy. There was only mild hyperlactic acidemia, 
However, in urine, amounts of lactate and 3-hydroxy- 
butyrate together with a complex pattern of organic acids
Table 2
Enzyme activities (mU/mg protein) in liver tissue (600 g supernatant)
NADH:Q, SCC QCC COX
(Complex I) (Complex II+III) (Complex III) (Complex IV)
____________________ _____ ___________ ____ _ _________  ___ ___ ______________________________ _^ ^
Control range 4.1-10 (n =  I0) 6.0-50 (»= 14) 69-107 (n=4) 14—108 (n= 11 )
Patient 1 6.3 4.4 23 74
Patient 2 3.1 41 71
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Table 3
Clinical and laboratory features in six children with complex III deficiency
Patient Sex Age at onset Clinical features Course Bruin imaging Blood lactate Lact/pyr CSF lactate 
(mmol/1) ratio (nmiol/1)
1 Sperl et al., 1988 f
3 f
Birth
2 Wendel et ai., 1995 in Birth
Birth
Intrauterine growth retardation 
Hyperlactic acidemia, Fanconi syndrome 
Developmental delay 
Hypotonia 
Retinopathy
Intrauterine growth retardation 
Hyperlactic acidemia, Fanconi syndrome 
Developmental delay 
Hypotonia
Intrauterine growth retardation 
Hyperlactic acidemia 
Failure to thrive 
Hypotonia
Pyramidal /" e xtra py ram itial symptoms 
Mental regression, neuropathy 
Ophthalmoplegia 
Tapetoretinal degeneration 
Exercise intolerance 
W,P.W. syndrome 
Growth retardation 
m 15 months Proximal muscle weakness
m 7 years
Hypotonia 
Hypotonia 
Exercise intolerance
Progressive (died at 8 months) CT-scan: Normal
Progressive (died al 7 months) Ultrasonography: Normal
Stable
Progressive
Slowly progressive
Stable
M RI-scnn: Cortical atrophy
M RI-scan: Normal
CT-scan: Normal
5 .6-18,U
1.4-3.5
Ultrasonography and MRI-scan: Normal 3.0-10.0
3.0
2.6
41
41
38-56
n.d.
n.d.
n.d.
n.d.
n.d.
5,3
7.7
1.0
n.d.
n.d.: not determined.
were markedly increased, suggestive of a respiratory chain 
defect. Despite symptomatic treatment in combination with 
menadione and riboflavine he deteriorated gradually. 
Eventually he died of respiratory distress at the age of 7 
months. Patient 3 presented at the age of 3 months with 
muscular hypotonia and failure to thrive. Lactate con­
centrations were clearly elevated in blood, cerebrospinal 
fluid and urine. Treatment with a ketogenic diet, vitamin E 
and ß -carotene did not show any effect on lactate con­
centrations. At the age of 3 years she was still severely 
retarded in growth and showed mildly impaired psychomo­
tor development. In Patient 4 psychomotor development 
was normal until the age of 7 years, then he developed a 
progressive loss of concentration and learning abilities and 
exercise intolerance. At 14 years he was referred because 
of deterioration with episodes of apathy and diminished 
consciousness, due to epileptic insults. He developed 
muscular* hypertonia, with contractures in all four ex­
tremities, hyperrigidity and dyspraxia. There was only mild 
hyperlactic acidemia, while lactate was distinctly elevated 
in cerebrospinal fluid. An MRI scan showed a hypoplastic 
cerebellar vermis inferior with wide ventricles and cister- 
nae. Neurophysiological tests revealed brainstem dysfunc­
tion. One year later he suffered from mental regression,
»
tapetoretinal degeneration, polyneuropathy and worsening 
of the hypokinetic hyperrigidity.
3.2. Patients with isolated myopathy
Patients 5 and 6 presented with myopathic features
within the first years of life. Both did not have distinctly 
elevated blood lactate concentrations. Patient 5 had a 
normal psychomotor development in the first year of life 
and was able to walk at 14 months. A few months later he 
was referred because of walking difficulties and dystrophy. 
He had a general muscular hypotonia, and suffered from 
loss of muscular strength and exercise intolerance. He 
developed joint contractures. Intellectual development was 
completely normal, but his motor abilities have gradually 
declined. At the age of 5 years he suffered from severe 
hypotonia and was unable to walk. Patient 6 presented at 
the age of 9 months with hypotonia and mild psychomotor 
developmental delay. No other organs were involved, and 
height growth was normal. Exercise intolerance and mus­
cle weakness appeared not to be progressive at the age of 5 
years.
4. Discussion
Deficiency of complex III of the respiratory chain is rare 
and so far no more than about 25 patients with an isolated 
defect of complex III have been reported (Morgan-Hughes 
et al., 1982; Hayes et al., 1984; Kennaway et al., 1984; 
Papadimitriou et al., 1984; Morgan-Hughes et al., 1985; 
Darley-Usmar et al., 1986; Reichmann et al., 1986; Mor­
gan-Hughes et al., 1987; Birch-Machin et al., 1989; 
Bouzidi et al., 1993; Marin-Garcia et al, 1995). The six 
children with isolated complex III deficiency reported here 
represent approximately 2% of subjects in whom a respira-
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tory chain defect has been identified in our laboratory. That 
our figure is much lower than that of Rustin et al. (Rustin 
e t  al., 1994), who found complex III deficiency in 15% of 
identified respiratory chain defects, can be attributed to the 
fact that in our study only patients with an isolated and 
markedly reduced complex III activity were taken into 
consideration. Kennaway (1988) summarized clinical and 
biochemical findings of 14 preponderantly adult subjects 
with isolated complex III deficiency. In the patients 
worked up in that review a variety of indirect methods 
were applied to pinpoint the site of the defect in the 
respiratory chain. In fresh muscle specimens the diagnosis 
was based on markedly reduced oxidation rates of NAD + - 
linked substrates and succinate together with normal 
ascorbate+tetramethylphenylenediamine (TMPA) oxida­
tion rates. By that approach it is not possible to differen­
tiate between a defect in the region of coenzyme Q and a 
defect in complex III. In other patients an isolated defect of 
complex III was concluded indirectly from a reduced 
activity from both rotenone-sensitive NADH:cytochrome c 
oxidoreductase and succinatexytochrome c oxidoreductase 
and normal activities for succinate dehydrogenase and 
cytochrome c oxidase. In some cases low levels of 
cytochrome b and also of cytochrome c { in combination 
with normal levels of cytochrome aa3 were used to confirm 
the defect of complex III. However, by all the indirect 
methods applied, it is not possible to localize the defect 
unequivocally to complex III and to exclude definitely 
coenzyme Q deficiency or a combination of complex III 
deficiency with defects of complex I and/or complex IV. 
Combinations of these respiratory chain defects occur 
frequently (Kennaway, 1988; Ruitenbeek et al., 1989; 
Robinson, 1993) and among our patients we found at least 
ten.
In the present study complex III deficiency was demon­
strated in each patient by severely reduced activity of 
decylubiquinolxytochrome c oxidoreductase in muscle 
tissue, whereas activities of complex I and IV were found 
to be normal In this way we could localize the defect in 
the respiratory chain precisely and exclusively to complex 
III. The residual activity varied between 13 and 45% of the 
lowest control value, except for Patient 6 , whose muscle 
showed an 80% residual activity.
Among our patients only one presented with en­
cephalomyopathy of later onset type (presentation of that 
phenotype in childhood or adult life), which is the most 
frequently reported phenotype of complex III deficiency, 
characterized by various combinations of muscle weak­
ness, intellectual impairment and cerebral motor disorders 
(Morgan-Hughes et al.} 1982; Kennaway et al., 1984; 
Morgan-Hughes et al., 1985; Darley-Usmar et al., 1986; 
Reichmann et al., 1986; Slipetz et al., 1991). The rare 
occurrence of this phenotype in our series can be explained 
by the fact that in our laboratory biochemical studies on 
muscle specimens are performed predominantly from a 
pediatric population.
Three patients presented with a neonatal multiorgan
disorder, characterized by a combination of neurological 
disease, lactate elevation in blood and cerebrospinal fluid, 
and in two cases renal dysfunction. In common, these 
children presented with intrauterine growth retardation and 
postnatal failure to thrive. Since intrauterine energy de­
mands are low compared to postnatal life and fetal energy 
metabolism is provided with ample glucose, with lactic 
acid being carried off by placental circulation, intrauterine 
growth retardation may be directly attributed to impair­
ment of oxidative phosphorylation.
Multiorgan disorder was biochemically verified in two 
patients by demonstrating complex III deficiency in skelet­
al muscle and liver. In the patients in whom multiorgan 
involvement was present according to clinical symptoms, 
proximal tubular abnormality, indicating kidney in­
volvement, was relatively frequently encountered. Renal 
tubular dysfunction, frequently reported in lethal infantile 
disease due to cytochrome c oxidase deficiency (DiMauro 
et al., 1985, 1990), appears to occur particularly frequently 
in complex III deficiency (Rötig et al., 1990; Jackson et 
al., 1995; Morris et al., 1995). In two infants myopathie 
features dominated the clinical picture. In both patients 
hyperlactic acidemia was absent. This observation suggests 
that in these patients the disease was restricted to skeletal 
muscle. Muscle biopsies of all patients showed nonspecific 
morphological changes, but no ragged red fibres, in 
contrast to reports on older patients (Morgan-Hughes et al., 
1985).
Investigations of fibroblasts did not reveal clearly re­
duced activities of complex III as measured by de- 
cylubiquinolxytochrome c oxidoreductase and sue- 
cinatexytochrome c oxidoreductase assays, This indicates 
that the biochemical defect was likely not expressed in 
cultured skin fibroblasts of the four patients studied. To 
our knowledge, there is no paper in which diagnosis of 
complex III deficiency has been based unequivocally on 
reduced enzyme activities in fibroblasts, implying that 
using cultured fibroblasts is not appropriate in order to 
arrive at the diagnosis of complex III deficiency (Morris et 
al., 1995).
Heterogenous tissue involvement of oxidative phos­
phorylation defects is common and has been reported 
particularly in patients with cytochrome c oxidase de­
ficiency. In our patients with complex III deficiency tissue- 
specific expression of the defect could be explained either 
by a mutation in one of the nuclear genes encoding for the 
different subunits or by mutations in the mitochondrial 
genome under the assumption that different levels of 
heteroplasmy occur in different tissues. With respect to 
mtDNA, mutations affecting the cytochrome b gene or one 
of the 22 tRNAs can cause complex III deficiency. 
Mutations within one of the tRNAs are less likely to have 
occurred, because they usually give rise to combined 
defects of respiratory chain complexes, such as in MELAS 
and MERRF (Tulinius et a l, 1991 a,b; Bentlage et al., 
1995). Moreover, no deletions or common point mutations 
were found in our patients. However, in the presented set
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of patients a mutation in the cytochrome b gene might be 
responsible for isolated complex III deficiency. Taking the 
clinical features and the studies on the mitochondrial 
genome into consideration we favour the idea of mutations 
in nuclear genes. Although no isoforms of subunits of 
complex III have been reported in humans so far (Vaz­
quez-Acevedo et al., 1993), most probably genes encoding 
for polypeptides being involved in the tissue-specific 
expression or assembly of complex III are concerned. Such 
nuclear genes encoding for factors involved in the assem­
bly of complex III have been identified in yeast (Rosing et 
al., 1985; Wu and Tzagoloff, 1989). In humans tissue- 
specific regulation of complex V is reported (Akiyama et 
aL, 1994). Analogous genes involving complex III might 
exist.
In conclusion, we demonstrated that the clinical pre­
sentation of complex III deficiency in childhood is very 
heterogeneous. Obviously, there are no clinical findings 
which are specific for complex III deficiency, although 
neonatal Fanconi syndrome appears to be frequent.
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